Using MR-proADM to predict complications after kidney and liver transplants
MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation
This study is testing if measuring a specific protein can help doctors predict complications like delayed graft function and acute rejection in people who have received kidney or liver transplants.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | University of Rome Tor Vergata Academic / other |
| Locations | 1 site (Rome) |
| Trial ID | NCT06130046 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the sensitivity and specificity of MR-proADM levels as an early, non-invasive biomarker for diagnosing delayed graft function (DGF) and acute rejection (AR) in kidney and liver transplant recipients. By measuring MR-proADM levels pre-operatively and post-operatively, the study will develop a predictive model using machine learning to identify patients at risk for these complications. The goal is to improve early diagnosis and management of post-transplant complications, ultimately enhancing patient outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals who are kidney or liver transplant recipients at the University of Rome Tor Vergata.
Not a fit: Patients who have undergone re-transplantation, dual kidney transplantation, combined organ transplants, or have autoimmune diseases as an indication for transplant may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection and management of complications in transplant patients, potentially reducing morbidity and mortality.
How similar studies have performed: While MR-proADM has shown promise as a prognostic marker in other contexts, this specific application in kidney and liver transplantation is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Kidney transplant recipient at our Institution * Liver transplant recipient at our Institution Exclusion Criteria: * Re-transplantation * Dual kidney transplantation * Combined transplant (kidney-liver, kidney-pancreas) * Autoimmune disease as indication to transplant
Where this trial is running
Rome
- University of Rome Tor Vergata — Rome, Italy (Recruiting)
Study contacts
- Principal investigator: Roberta Angelico, PhD FEBS — University of Rome Tor Vergata
- Study coordinator: Roberta Angelico, PhD FEBS
- Email: roberta.angelico@med.uniroma2.it
- Phone: 0620908294
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.